Past Forum: 2017
London
Summary
Where High-Impact Global Initiatives Begin
The World Neuroscience Innovation Forum was a tailored, neuroscience gathering that built on the broad success of the flagship Annual Forums. The Neuroscience Forum took place in London at the Francis Crick Institute on 27 March 2017. It featured highly-interactive exchanges among neuroscience leaders, with the aim of turning insights into action. The Forum was being jointly hosted by Partners HealthCare and the Francis Crick Institute. It was a collaboration among them, leading pharmaceutical and biotechnology companies, investors and other academic centers. The goal of the Forum is to spark new insights, therapeutic paths and collaborations to combat neuroinflammation and neurodegeneration. The Forum convened international leaders from throughout the neuroscience community, including principals from the corporate, academic, government, foundation and investment sectors. The objectives:- Launch focused translation and commercialization collaborations to address unmet needs.
- Seed new and grow world-class international neuroscience teams that will lead to high impact commercial products.
- Initiate Springboard Challenge designed to position new international commercialization-oriented teams for substantial industry, government and philanthropic support.
- Increase interactions among top neuro-oriented investigators, investors, entrepreneurs, corporate leaders, philanthropists and government executives across Europe and in the US.
Program
Keynoters
Merit Cudkowicz, MD
- Chair, Dept of Neurology, MGH
- Julieanne Dorn Professor of Neurology, HMS
Michael Ehlers, MD, PhD
- EVP, Head of R&D, Biogen
Hilary Evans
- CEO, Alzheimer’s Research UK
Jean-François Formela, MD
- Partner, Atlas Venture
Michael Hayden, MD, PhD
- ,
Anne Heatherington, PhD
- SVP, Head of Data Sciences Institute, Takeda
Michael Hutton, PhD
- CSO, Neuroscience, Eli Lilly and Company
Brad Hyman, MD, PhD
- Director, MGH Alzheimer’s Disease Research Center, MGH
- John B. Penny, Jr. Professor of Neurology, HMS
Ole Isacson, MD, PhD
- Director, Neuroregeneration Research Institute, McLean
- Professor of Neurology & Neuroscience, HMS
Anne Klibanski, MD
- President & CEO, Mass General Brigham
- Laurie Carrol Guthart Professor of Medicine, HMS
John Lechleiter, PhD
- Chairman, Eli Lilly and Company
Gillian Leng, MD
- Deputy Chief Executive, National Institute for Health and Care Excellence
John Lepore, MD
- SVP, R&D Pipeline, GlaxoSmithKline
Min Li, PhD
- SVP, Global Head of Neurosciences, GlaxoSmithKline
Husseini Manji, MD
- Global Therapeutic Head, Neuroscience, Janssen Research & Development
David Mayhew, CBE
- UK Dementia Envoy; Chairman, Alzheimer’s Research UK
Bob Oliver
- CEO, Otsuka America Pharmaceutical
Peter Orszag, PhD
- Vice Chairman, Corporate and Investment Banking, Citigroup
Steven Paul, MD
- CEO, Voyager Therapeutics
Hugh Perry, PhD
- Professor of Experimental Neuropathology, University of Southampton
David Roblin, MD
- COO and Director of Scientific Translation, The Francis Crick Institute
Richard Rudick, MD
- VP Development Sciences, Biogen
Martin Samuels, MD`
- Chair, Department of Neurology, BWH
- Miriam Sydney Joseph Professor of Neurology, HMS
Alfred Sandrock, MD, PhD
- EVP, R&D and CMO, Biogen
Dennis Selkoe, MD
- Co-Director, Ann Romney Center for Neurologic Diseases, BWH
- Vincent and Stellla Coates Professor of Neurologic Diseases, HMS
Rudolph Tanzi, PhD
- Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH
- Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Howard Weiner, MD
- Director, Multiple Sclerosis Program, BWH
- Robert L. Kroc Professor of Neurology, HMS
Panels
Monday, March 27, 2017
Disease Modifying Therapies: Getting over the Technology Threshold
- Moderator: Jean-François Formela, MD, Partner, Atlas Venture
- Kate Bingham, Managing Partner, SVLS
- Min Li, PhD, SVP, Global Head of Neurosciences, GlaxoSmithKline
- Vivek Ramaswamy, CEO, Roivant Sciences
- Alfred Sandrock, MD, PhD, EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen
- Dennis Selkoe, MD, Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School
Expanding the Diagnostic Spectrum: Tools, Technologies, and Tracers
- Moderator: Bruce Rosen, MD, PhD, Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
- Roger Gunn, PhD, CSO, Imanova; Professor of Molecular Neuroimaging, Department of Medicine, Imperial College, London
- Jacob Hooker, PhD, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry, Athinoula A. Martinos Center, Massachusetts General Hospital; Associate Professor in Radiology, Harvard Medical School
- Robert Krieg, PhD, VP of MR Product Definition & Innovation, Siemens
- Eddie Martucci, PhD, CEO, Akili Interactive Labs
- Henrik Zetterberg, MD, PhD, Professor of Neurochemistry, Head of Lab, UCL; Professor of Neurochemistry, Head of Department, University of Gothenburg
1:1 Fireside Chat – John Lechleiter
- Moderator: Hilary Evans, CEO, Alzheimer’s Research UK
- John Lechleiter, PhD, Chairman, Eli Lilly and Company
Patient Interview
- Moderator: Martin Samuels, MD, Chair, Department of Neurology, Brigham and Women’s Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medical School
- Brenda and Stephen Whittle, PhD, Dementia Patient & Caregiver, Dementia Advocates and Volunteer Partners with ARUK (Alzheimer’s Research UK)
Neurodegeneration and Neuroinflammation: A Grand Unifying Theory for Drug Development?
- Moderator: Rudolph Tanzi, PhD, Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
- Christian Haass, PhD, Institute Head, German Center for Neurodegenerative Disease
- Michael Hayden, MD, PhD, President of Global R&D, CSO, Teva Pharmaceutical Industries
- Michael Hutton, PhD, CSO, Neuroscience, Eli Lilly and Company
- Roger Nitsch, MD, President, Neurimmune Holding AG
- Hugh Perry, PhD, Professor of Experimental Neuropathology, University of Southampton
Lunch Breakout: Depression and Neuroinflammation
- Moderator: Philip Iredale, PhD, VP Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer
- Declan Jones, PhD, VP, Neuroscience Lead, J&J London Innovation Centre, Johnson & Johnson
- Kerry Ressler, MD, PhD, CSO, McLean Hospital; Professor in Psychiatry, Harvard Medical School
The Promise and Current Role of Gene and Cell Therapy
- Moderator: Ole Isacson, MD, PhD, Principal Investigator Harvard Stem Cell Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School
- Timothy Cox, MD, Professor of Medicine Emeritus, Director of Research, Honorary Consultant Physician, University of Cambridge
- Brad Hyman, MD, PhD, Director, Massachusetts Alzheimer’s Disease Research Center, Massachusetts General Hospital; John B. Penney Professor of Neurology, Harvard Medical School
- Gillian Leng, MD, Deputy Chief Executive, National Institute for Health and Care Excellence
- Steven Paul, MD, CEO, Voyager Therapeutics
Next-Generation Therapies and Diagnostics: Big Data and Digital Health
- Moderator: Shawn Murphy, MD, PhD, Corporate Director of Research Information Systems and Computing, Partners HealthCare; Associate Professor of Neurology, Harvard Medical School
- Jenny Barnett, PhD, CSO, Cambridge Cognition
- John Gallacher, PhD Director, MRC Dementias Platform UK
- Husseini Manji, MD, Global Therapeutic Area Head, Neuroscience, Janssen R&D
- Richard Rudick, MD, VP Development Sciences, Biogen
- Howard Weiner, MD, Director, Multiple Sclerosis Program, Brigham and Women’s Hospital; Robert L. Kroc Professor of Neurology, Harvard Medical School
1:1 Fireside – Alfred Sandrock
- Moderator: Rudolph Tanzi, PhD, Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
- Alfred Sandrock, MD, PhD, EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen
Implementing Novel Models in Alzheimer’s Trials: How Can We Transform the Cost-Benefit Equation for Trials?
- Moderator: Reisa Sperling, MD, Director, Center for Alzheimer’s Research and Treatment, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School
- Iain Chessell, PhD, VP Neuroscience IMED MedImmune, AstraZeneca
- Michael Krams, MD, Global Head of Quantitative Sciences, Janssen Pharmaceuticals
- Craig Ritchie, MD, PhD, Professor of Psychiatry of Ageing University of Edinburgh
- Nadeem Sarwar, MD, PhD, President, AiM Institute, Eisai
The Crisis We Want: Are Healthcare Systems Prepared for a Disease-Modifying Drug?
- Moderator: Merit Cudkowicz, MD, Chair, Department of Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School
- Phyllis Ferrell, VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company
- Tim Ferris, MD, Senior Vice President of Population HealthCare Management, Partners HealthCare; Associate Professor of Medicine and Pediatrics, Harvard Medical School
- Geoff Huggins Director of Health Social Care and Integration, Scottish Government
- Bob Oliver, CEO, Otsuka America Pharmaceutical
Announcement and Discussion of the Springboard Challenge
- Moderator: Christopher Coburn, Chief Innovation Officer, Partners HealthCare
- John Lepore, MD, SVP, R&D Pipeline GlaxoSmithKline
Sponsors
